Clinical trial registry record

Implementing Geriatric Assessment for Dose Optimization of Cyclin-dependent Kinase (CDK) 4/6-inhibitors in Older Breast Cancer Patients

A registered PHASE3 study indexed because it matched monitored longevity research terms. Registry status: Recruiting. Registration does not establish safety or effectiveness.

Plain-language guide

Five questions to ask about this record

What this is
A clinical study registration, not a result or recommendation.
Why it may matter
The registry currently reports Recruiting.
Evidence
Registered phase 3 study.
Main limitation
Registration does not prove that the intervention works, is safe, or is available to you.
What changed
Registry metadata was last updated November 19, 2024.
Where to verify
Open the primary registry below for eligibility, locations, contacts, and current status.
Registry ID
NCT06044623
Last registry update
November 19, 2024
Status
Recruiting
Phase
Phase 3
Sponsor
Region Örebro County
Enrollment
495
Countries
Finland, Greece, Italy, Norway, Spain, Sweden
Match confidence
100%
Source feed
ClinicalTrials.gov
Automated source synopsis

A registered PHASE3 study indexed because it matched monitored longevity research terms. Registry status: Recruiting. Registration does not establish safety or effectiveness.

Evidence snapshot

What the source actually supports

Evidence stage
Phase 3
Study design
RANDOMIZED · PARALLEL · TREATMENT · NONE
Evidence population
Human clinical study registration
Participants
495
Population
ALL · 70 Years
Duration
2024-04-01 to 2029-05-31
Intervention
CDK 4/6 inhibitors; Endocrine therapy
Comparator
Full initial dose of CDK 4/6-inhibitor (vulnerable/frail patient cohort)
Outcomes measured
Time to treatment failure — Up to 5 years from treatment initiation; Overall treatment utility (OTU) — Three months after treatment initiation; Overall survival — Up to 5 years from treatment initiation; Progression free survival — Up to 5 years from treatment initiation; Time to chemotherapy initiation — Up to 5 years from treatment initiation; Frequency of adverse events — Up to 5 years from treatment initiation; Assessment of Quality of life — Until disease progression, participant / physician decision to stop, death, or up to 24…; Time until Quality of life deterioration — Until disease progression, participant / physician decision to stop, death,…; Cost effectiveness — Up to 24 months from treatment initiation
Reported result
No reusable finding-level result is available in this record.

Main limitationThis is a study registration. No reusable structured result is available here, so it cannot show whether the intervention worked or was safe.

Safety and approvalEligibility, adverse-event details, and clinical decisions must be checked in the official registry and with qualified clinicians. Trial registration is not regulatory approval and does not establish that an intervention is available.

Source supportStructured registry protocol metadata; no finding-level conclusion is generated.

Trial stage · Phase 3A trial phase describes development stage; it does not establish a positive result.
Phase 1Phase 2Phase 3Phase 4

Registration and recruitment status do not establish safety, efficacy, or regulatory approval.

Why this record appears here · 100% topic match

The title, summary, or source keywords matched one or more topics followed by immortal.life. A higher percentage means a stronger topic match; it does not rate safety, effectiveness, or study quality.

  • Cancer and ageing · 100%Title contains controlled topic terminology. Summary contains controlled topic terminology. Source terminology contains a controlled topic term. Title supplies ageing or longevity context.

Automated source check 100% · update recency 65%. These figures help sort records; they are not medical ratings.

cancer and aging
Read the original source →Export JSON